KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Common Equity (2019 - 2026)

GoodRx Holdings' Common Equity history spans 7 years, with the latest figure at $616.3 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 14.96% to $616.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $616.3 million, a 14.96% decrease, with the full-year FY2025 number at $616.3 million, down 14.96% from a year prior.
  • Common Equity hit $616.3 million in Q4 2025 for GoodRx Holdings, up from $600.7 million in the prior quarter.
  • Over the last five years, Common Equity for GDRX hit a ceiling of $895.4 million in Q2 2023 and a floor of $600.7 million in Q3 2025.
  • Historically, Common Equity has averaged $753.1 million across 5 years, with a median of $774.2 million in 2022.
  • Biggest five-year swings in Common Equity: soared 180.29% in 2021 and later dropped 25.24% in 2024.
  • Tracing GDRX's Common Equity over 5 years: stood at $831.7 million in 2021, then fell by 2.03% to $814.8 million in 2022, then dropped by 6.49% to $762.0 million in 2023, then fell by 4.9% to $724.7 million in 2024, then decreased by 14.96% to $616.3 million in 2025.
  • Business Quant data shows Common Equity for GDRX at $616.3 million in Q4 2025, $600.7 million in Q3 2025, and $643.0 million in Q2 2025.